πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 14,889 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12090142

Combination therapy for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090145

Combination therapy for treating or preventing depression or other mood diseases

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091386

D-amphetamine compounds, compositions, and processes for making and using the same

Zevra Therapeutics, Inc. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090170

Methods of treating glioblastomas

The Regents of the University of California Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091388

Solid state forms of Reproxalap

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091426

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

NURIX THERAPEUTICS, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091692

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090139

Formulations comprising triptan compounds

Tonix Medicines, Inc. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091666

Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091661

Organic compositions to treat HSF1-related diseases

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091486

Block copolymer and micelle compositions and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091460

Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091463

Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)

Orionis Biosciences, Inc Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091675

Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090140

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091440

IL2 and peptide-MHC complex fusion proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084497

SIRP1Ξ± targeted chimeric proteins and uses thereof

Orionis Biosciences, Inc Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084489

Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084514

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084727

Microbiome markers and therapies for autism spectrum disorders

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084502

CD33-binding polypeptides and uses thereof

Inhibrx Biosciences, Inc. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084515

Compositions and methods for treatment of diabetic macular edema

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12083162

Universal nanosponge for treating respiratory viral infection

The Regents of the University of California Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12083229

Ocular drug delivery formulation

INMED PHARMACEUTICALS INC. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted